Erenumab reduces headache frequency in minor TBI

  • Ashina H & al.
  • J Headache Pain
  • 3 jun. 2020

  • de Kelli Whitlock Burton
  • Clinical Essentials
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

Takeaway

  • Patients who received erenumab for persistent posttraumatic headache (PTH) following mild traumatic brain injury (TBI) reported fewer moderate-to-severe headache days a month.

Why this matters

  • Despite the prevalence of PTH, no approved pharmacological therapies are available, and research on effective treatments is limited.

Study design

  • 100 patients with a history of persistent headache attributed to mild TBI received 140-mg erenumab injections every 4 weeks for 12 weeks.
  • Funding: Novartis Healthcare A/S.

Key results

  • Headache phenotypes included chronic migraine-like headache (53%), combined episodic migraine-like/tension-type-like headache (TTH; 34%), and ‘pure’ chronic TTH-like headache (13%).
  • 89% were current users of acute headache medication.
  • 74% had used preventive medication, more than half of whom had not gained relief from ≥3 preventive medications.
  • Decrease from baseline in mean number of headache days during study period:
    • Moderate-to-severe intensity: 15.7±9.6 to 2.8±6.8 days/month.
    • Headaches of any severity: 24.6±6.1 to 1.7±6.9 days/month.
  • 28% of patients reported ≥50% reduction in the mean number of headache days, and 47% reported ≥25% decrease.
  • The most common adverse events (AEs) were constipation (n=30) and injection-site reactions (n=15), and no serious AEs were reported.

Limitations

  • Single-center, nonrandomized study.